Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data

Table 2

Univariate analysis of axillary in patients from the test set (n = 175).

Characteristics	OR	95% Cl	values
Age	0.990	0.956–1.027	0.602
Clinical T stage
1	REF
2	0.552	0.174–1.751	0.313
3	1.818	0.300–11.023	0.516
4	0.818	0.179–3.739	0.796
Clinical N stage
1	REF
2	2.723	1.096–6.762	0.031
3	4.566	1.007–20.714	0.049
US of lymph nodes
Negative	REF
Positive	4.102	17.47–9.631	0.001
Histologic type
IDC	REF
Other	0.570	0.123–2.649	0.473
NAC regimes
A	REF
T	0.455	0.084–2.469	0.361
A + T	1.131	0.418–3.062	0.808
NAC cycles
<4	REF
4–6	0.553	0.063–4.844	0.593
<6	0.769	0.085–6.944	0.815
Breast surgery
BCS	4.992	1.833–13.598	0.002
Mastectomy	REF
ypT stage
0	REF
1–4	1.806	0.523–6.237	0.350
Histologic grade
I/II	REF
III	2.211	0.828–5.904	0.113
Ki-67
<14	3.346	1.544–7.252	0.002
≥14	REF
HER2
Negative	2.367	1.011–5.538	0.047
positive	REF
LVI
Negative	REF
Positive	3.634	1.329–9.937	0.012

OR = odds ratio; CI = confidence interval; REF = reference; HER2 = human epidermal growth factor receptor 2; LVI = lymphovascular invasion. Only patients with available data were used in the analysis.